Transformative Therapies For Retinal Diseases


Our Pipeline

Learn More

CLINICAL TRIALS

Learn More

INVESTOR OVERVIEW

Learn More

Our Story

Iveric Bio is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs.

Who We Are


An experienced, passionate team with a proven track record in collaborative clinical development and commercialization of novel therapies. Our team is focused on delivering strategic solutions that better the lives of patients, eyecare professionals, and more. With expertise in ophthalmology and retinal diseases, we welcome the challenges of the future.

Read More

What We're Doing


Our strategy is focused on developing multiple, complementary assets to treat a broad spectrum of retinal diseases. We intend to do this by potentially studying Zimura in indications beyond geographic atropy secondary to dry AMD and autosomal recessive Stargardt disease and by advancing the development of IC-500 our HtrA1 inhibitor.

Having both Zimura and IC-500 in our pipeline positions us to potentially provide treatments for patients with various types and stages of AMD, the leading cause of vision loss in the elderly. We are also developing novel gene therapy technology to treat orphan inherited retinal diseases (IRDs). IRDs can be caused by many different mutations of a single gene. Our strategy is to develop mutation independent treatment options to potentially treat the entire group of patients with a particular IRD.

Read More

Many Perspectives, One Vision.

We are a collection of inquisitive minds leveraging decades of clinical expertise and marketing knowledge. Discover more about our experience, and what makes Iveric Bio unique, by clicking the photos below.

Leadership

Glenn P. Sblendorio

Chief Executive Officer

Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Pravin U. Dugel, MD

President

Pravin U. Dugel, MD, is President. Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.

Dr. Dugel is a member of the board of directors and current Chair of Orbis International’s Medical Advisory Board/Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.

Dr. Dugel graduated summa cum laude from Columbia University in New York City. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.

Keith Westby

Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of Iveric Bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a BS in applied physics from the State University of New York, College at Geneseo, a MS in engineering management from Drexel University, and a MBA degree from Columbia Business School.

David F. Carroll

Chief Financial Officer

David Carroll, M.B.A, is the Chief Financial Officer of Iveric Bio. Mr. Carroll joined the Company in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller, and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb. Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Abraham Scaria, PhD

Chief Scientific Officer

Dr. Scaria has more than 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. For much of his career, Dr. Scaria has specialized in viral gene therapy vectors and ocular gene therapy, having served as Senior Scientific Director of Gene Therapy and Ophthalmology at Genzyme-Sanofi and subsequently Head of Gene Therapy Research at Sanofi. Most recently, Dr. Scaria was Vice President and Head of Ophthalmology at Casebia Therapeutics, where he oversaw efforts to develop gene-editing–based therapies for inherited retinal diseases. He earned his doctorate in biochemistry and molecular biology from Indiana University School of Medicine and conducted postdoctoral research at St. Louis University School of Medicine and at the University of Washington School of Medicine in Seattle. Dr. Scaria has more than 45 publications and currently serves on several committees for the American Society for Gene and Cell Therapy.

Amy Sheehan

Chief Human Resources Officer

Amy Sheehan is the Senior Vice President & Chief Human Resources Officer at Iveric Bio. Ms. Sheehan joined the Company in 2014 and brings over 20 years of human resources experience in the biotechnology and manufacturing industries. Prior to joining Iveric Bio Ms. Sheehan led Human Resources for the Electronic Systems Division of Parker Hannifin, a publicly traded Fortune 250 global company. Earlier in Ms. Sheehan’s career she held leadership positions of increasing responsibility in human resources at OSI Pharmaceuticals, a publicly traded biotechnology company. Throughout Ms. Sheehan’s career she oversaw Human Resources teams and led successful HR strategies in talent acquisition, culture, total rewards, leadership development, and training. She holds a MS in human resources management and a BA in psychology from Hofstra University.

Dhaval Desai

SVP & Chief Development Officer

Dhaval Desai, PharmD, joined IVERIC bio as Chief of Staff in 2020 after serving as Vice President and Medical Unit Head of US Ophthalmics at Novartis. During his time at Novartis Mr. Desai was responsible for the establishment of a US ophthalmics unit and developing a comprehensive franchise strategy. Prior to Novartis Mr. Desai held multiple leadership roles in ophthalmology-focused companies including Aerpio Pharmaceuticals where he served as Vice President of Medical Affairs and Chief Strategic Officer and ThromboGenics where he served as Global Director, Medical Affairs. Mr. Desai received his PharmD and completed his post-doctoral fellowship at Rutgers University. 

Evelyn Harrison

Chief Clinical Operations Officer

Evelyn Harrison, MBA, is the Senior Vice President & Chief Clinical Operations Officer of Iveric Bio. She brings more than 23 years of management and clinical research experience. Prior to joining Iveric Bio, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a BA degree in biology from Hofstra University and an MBA from Manhattan College.

Guangping Gao, PhD

Chief Strategist, Gene Therapy

Dr. Gao is the Co-Director, Li Weibo Institute for Rare Diseases Research; Director, Horae Gene Therapy Center and Viral Vector Core; Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research, at the University of Massachusetts Medical School. He is an elected fellow of both the US National Academy of Inventors (NAI) and the American Academy of Microbiology; and the current President of the American Society of Gene and Cell Therapy.

Dr. Gao is an internationally recognized gene therapy researcher who has played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field, providing technology to enable potential treatments for many currently untreatable human diseases. For nearly 30 years of his scientific research career, Dr. Gao has primarily focused on molecular genetics and viral vector gene therapy for rare genetic diseases, with research encompassing disease gene cloning, causative mutation identification, pathomechanism investigation, animal modeling, novel viral vector discovery and engineering for in vivo gene delivery, vector biology, preclinical and clinical gene therapy product development, and viral vector manufacturing for preclinical and clinical gene therapy applications, as well as development of technology platforms for novel approaches for human gene therapy.

Dr. Gao has published 267 research papers, 6 book chapters, and 5 edited books and serves as Editor of Human Gene Therapy, Senior Editor of the Gene and Cell Therapy book series, Associate Editor of Signal Transduction and Targeted Therapy, and on the editorial boards of several other gene therapy and virology journals. Dr. Gao holds 135 patents with 239 additional patent applications pending. Dr. Gao's inventions have been licensed to and are currently in development by over 10 pharmaceutical companies. Recently, Dr. Gao was ranked as #4 on Nature Biotechnology’s list of the World’s Top 20 Translational Researchers for 2017.

Todd D.C. Anderman

General Counsel & Corporate Secretary

Todd D.C. Anderman is Sr. Vice President, General Counsel & Corporate Secretary of Iveric Bio. Mr. Anderman joined the Company in 2015 after representing the Company since 2012 while practicing corporate law at Wilmer Cutler Pickering Hale and Dorr LLP. While at WilmerHale, Mr. Anderman’s practice focused on representing life sciences and technology companies. Mr. Anderman began his career as a corporate attorney at Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising on merger, acquisition, divestiture, licensing, and financing transactions. Mr. Anderman received his BA in government and philosophy from the College of Arts & Sciences at Cornell University and his JD from the University of Pennsylvania Law School.

Xiao-Ping Dai, PhD

Chief Technical Officer

Dr. Xiao-Ping Dai is Chief Technical Officer of Iveric Bio, responsible for manufacturing and CMC development of the product pipeline. She joined the company in 2019.

Dr. Dai has more than 20 years of experience in the biopharmaceutical industry, specialized in product and process development and manufacturing. She has successfully developed processes and managed overall CMC development for more than 30 different biological products including monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, multi-specific antibodies and vaccines, from preclinical development through commercialization, including Opdivo and Yervoy. Dr. Dai has a proven track record of internal and external development, with CDMOs/CMOs, managing multiple partnerships and collaborations, technology transfers, scale-ups, process performance qualifications (PPQ) and regulatory filings.

Prior to joining Iveric Bio, Dr. Dai was Chief Technologist and VP of Process and Technology Development at WuXi Advanced Therapy, a CDMO where she built and led an organization engaged in process and technology platform development, serving cell and gene therapy clients. Prior to joining WuXi, Dr. Dai was Sr. Director of Biologics Development and Manufacturing at Celgene Corporation, where she built and led a strong technical team and successfully delivered on multiple internal and external programs. Prior to Celgene, Dr. Dai had over 13 years of effective functional and cross-functional leadership and technical experience in Biologics Development at BMS, Medarex and Regeneron Pharmaceuticals, and before that at NJIT, where she received her PhD in Chemical Engineering.

Board of Directors

Adrienne L. Graves, PhD

Former Chief Executive Officer, Santen. Inc.

Adrienne L. Graves, PhD, is a visual scientist by training and a global industry leader in ophthalmology. As the former Chief Executive Officer of Santen Inc., the US subsidiary of the 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Senior Vice President of Worldwide Clinical Development (US, Europe, and Japan) for seven years and Chief Executive Officer for eight years. Prior to Santen, she spent nine years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology.

Dr. Graves currently serves as an independent director on multiple corporate boards including Greenbrook TMS, Nicox S.A., Oxurion NV, and Surface Pharmaceuticals. She is also a director on the following foundation boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, Foundation Fighting Blindness Retinal Degeneration Fund, Retinal Global and KeepYourSight Foundation.

Dr. Graves co-founded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic World Leaders (OWL). She received her AB in psychology from Brown University, her PhD in psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Axel Bolte

President and CEO, Inozyme Pharma, Inc. and Investment Advisor, HBM Healthcare Investments AG

Axel Bolte as served on the board of directors for Iveric Bio since August 2007. Since March 2003, Mr. Bolte has served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry, also serving as a venture partner to HBM Partners AG beginning in February 2017. In February 2017, Mr. Bolte began serving as President and Chief Executive Officer of Inozyme Pharma Inc., a private biotechnology company. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. Mr. Bolte currently serves on the board of directors of Nabriva Therapeutics AG and previously served on the board of directors of PTC Therapeutics, Inc., both of which are publicly traded biotechnology companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an MBA from the University of St. Gallen, Switzerland.

Calvin Roberts, MD

President and CEO, Lighthouse Guild

Calvin W. Roberts, MD is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. Dr. Roberts is the President and CEO of Lighthouse Guild, the leading provider of services to those with vision loss. Formerly, Dr. Roberts served as Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts has been a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a founding member of the board of directors of Alimera Sciences. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson, and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals.

Dr. Roberts received an AB from Princeton University and his MD from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.

Glenn P. Sblendorio

Chief Executive Officer Iveric Bio

Glenn Sblendorio, MBA, is Chief Executive Officer of Iveric Bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer, and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the board of directors of Iveric Bio from 2013 to 2016 and rejoined the board in May 2017. Prior to joining Iveric Bio, he served as President and Chief Financial Officer and member of the board of directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Jane Pritchett Henderson

Chief Financial Officer, Adagio Therapeutics, Inc.

Jane Pritchett Henderson has more than 32 years of experience in the life sciences industry and health care investment banking. She currently serves as Chief Financial Officer at Adagio Therapeutics, a company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. Previously Ms. Henderson served as Chief Financial Officer at Turnstone Biologics, a clinical-stage immuno-oncology company. Prior to Turnstone, Ms. Henderson served as CFO and Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Sesen Bio Inc., a publicly-traded biologics oncology company, and Akero Therapeutics, a publicly traded, clinical-stage company focused on NASH.

Mark S. Blumenkranz, MD

HJ Smead Professor Emeritus, Department of Ophthalmology, Stanford University

Mark S. Blumenkranz, MD, MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University, where he is the co-director of the Ophthalmic Innovation Program. Dr. Blumenkranz is a co-founder and the Chief Executive Officer and Chairman of Kedalion Therapeutics and currently serves as a director of Verana Health, BVI Visitec, Combangio Corporation, and One Medical (ONEM:NASDAQ). Dr. Blumenkranz is also a Managing Director of Lagunita Biosciences, an early stage biotechnology and medical investment company and incubator.

He was a co-founder and served on the boards of Optimedica Corporation (acquired by AMO), Peak Surgical (acquired by Medtronics), Adverum Biotechnologies (ADVM:NASDAQ), and Oculeve (acquired by Allergan). He also co-founded Verana Health (formerly Digisight Technologies) and Combangio Corporation, both clinical-stage privately held venture-backed companies in Silicon Valley, and continues to serve on their boards. In the past he served as an independent Director at Oculex Pharmaceuticals (acquired by Allergan), and Presbia.

Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company formation and is the author of more than 160 peer-reviewed articles and more than 18 issued patents including the Pascal and Catalys lasers. He is a past president of the American University Professors of Ophthalmology, the Retina Society, the Macula Society, and a Fellow Emeritus of the Corporation of Brown University, where he served as the Chair of the Medical School Committee.

Dr. Blumenkranz received his undergraduate, graduate, and medical degrees at Brown; his ophthalmic residency training at Stanford; and a fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute. He served as the Chair of the Ophthalmology Department at Stanford from 1997 until 2015 and played a leading role in the planning, fundraising, and construction of the Byers Eye Institute there.

Scientific Advisors

  • Visionary
  • Steering
  • Imaging
Jeffrey Heier, MD

Ophthalmic Consultants of Boston

Dr. Jeffrey Heier is the Co-President and Medical Director of Ophthalmic Consultants of Boston (OCB). He is a leading researcher for new treatments in vitreoretinal disease, surgical techniques, and diagnostic imaging of the retina. Dr. Heier is on the Executive Board of the Retina Society and the ASRS and is Immediate past president of the New England Ophthalmological Society. He is a scientific advisor to many biotechnical or pharmaceutical companies, lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center, and vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.

Peter Kaiser, MD

Cole Eye Institute

Dr. Peter K. Kaiser graduated magna cum laude with Highest Honors from Harvard College and Harvard Medical School. He completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute, Cleveland, Ohio. As a National Institute of Health-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration (AMD) and diabetic retinopathy. In addition, Dr. Kaiser is actively involved in clinical research as Study Chairman of five major, multi-center, international clinical trials, and principal investigator in numerous studies for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR). Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored seven textbooks, and more than 250 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Senior Achievement Awards and is listed as one of the “Best Doctors in America.” Finally, he is the team ophthalmologist for the Cleveland Cavaliers (National Basketball Association).

Adnan Tufail, MBBS, MD

Moorfields Eye Hospital

Dr. Adnan Tufail is a leading ophthalmologist in London, specializing in medical retina disorders and cataract surgery in the context of retinal diseases. He is the clinical and research lead at Moorfields Eye Hospital for age-related macular degeneration (AMD), co-leads the €16 million Macustar Consortium, which unites industry and academia to drive dry AMD research, and is the clinical lead of the largest-ever UK Medical Research Council grant to develop novel non-VEGF anti-angiogenic therapies.

Dr. Tufail’s current areas of clinical research include novel drug and cell therapies for AMD, diabetic retinopathy and myopic degeneration, as well as a number of rare and complex retina disorders. Professor Tufail has published extensively in clinical and scientific journals and is invited to lecture widely around the world.

Anat Loewenstein, MD

Tel Aviv University

Dr. Anat Loewenstein is Professor of Ophthalmology, Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University, and Chairman of the Department of Ophthalmology, Tel Aviv Medical Center. She completed her residency in the Department of Ophthalmology at the Tel Aviv Medical Center, and her fellowship in vitreoretina at the Wilmer Institute, Johns Hopkins University Hospital in Baltimore.

She was the leader behind the development of novel technology for early detection of macular degeneration, as well as the development of automated technology for detection of retinal disease activity and the development of augmented virtual reality to replace the operating microscope. She has published more than 380 papers in peer-reviewed journals, and contributed multiple chapters to ophthalmology textbooks.

She serves as the editor of the journal Case Reports in Ophthalmology, is the chair of the Ministry of Health’s ethics committee and a member of the National Council of Surgery and Anesthesia.

Carl D. Regillo, MD, FACS

Wills Eye Hospital

Dr. Carl D. Regillo is the Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia. He received his medical degree from Harvard Medical School and performed both his ophthalmology residency and vitreoretinal fellowship at Wills Eye Hospital. He is the founder and former Director of the Wills Eye Clinical Retina Research Unit, former Chairman of the American Academy of Ophthalmology Retina Basic and Clinical Science Course, former Chairman of the Wills Eye Institutional Review Board, and prior Director of the Wills Eye Retina Fellowship.

He has authored over 200 publications along with over 50 book chapters and eight major books. He has been an investigator on numerous major clinical trials developing new treatments for retinal disorders such as macular degeneration and diabetic retinopathy. He lectures worldwide. He has served on the scientific editorial board for the American Journal of Ophthalmology, Review of Ophthalmology, Current Opinion in Ophthalmology, Yearbook of Ophthalmology, Retinal Physician, and Retina Today. He is a recipient of the American Academy of Ophthalmology Achievement, Senior Achievement, and Secretariat Awards along with the American Society of Retina Specialists Honor and Senior Honor Awards. He also has been listed multiple times through the years as a retina “Top Doctor” in the Philadelphia Magazine, Philadelphia Life, Mainline Today, and South Jersey Magazine.

Charles C. Wykoff, MD, PhD

Retina Consultants of Houston

Dr. Charles C. Wykoff is Director of Research at Retina Consultants of Houston and elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. He graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his medical degree from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. He completed ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute where he served as Chief Resident/Co-Director of Ocular Trauma and was awarded a Heed Fellowship and the Ronald G. Michels Fellowship Award. Dr. Wykoff is passionate about translational research and clinical trial design, and has published over 130 peer-reviewed manuscripts.

His research interests pertain to angiogenesis and retinal vascular diseases, including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgical topics such as retinal detachment and macular surgery. Dr. Wykoff has been awarded the AAO Secretariat and Achievement Awards as well as the ASRS Honor and Senior Honor Awards. He was a founding member of the Ophthalmology Retina Editorial Board and is involved with multiple scholarly societies including the Macula Society, the Retina Society, and the Vit-Buckle Society. He is actively involved in entrepreneurial activities and serves on multiple scientific advisory boards for companies spanning the innovative process from early to late stage development. His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for blinding diseases.

David S. Boyer, MD

Retina Vitreous Associates Medical Group

Dr. David S. Boyer is a board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena, and Tarzana, California. Dr. Boyer is an Adjunct Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA. He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases.

Donald J. D'Amico, MD

Weill Cornell Medical College

Dr. Donald J. D’Amico, Professor and Chairman of Ophthalmology at Weill Cornell Medical College and Ophthalmologist-in-Chief at New York Presbyterian Hospital, is an internationally recognized leader in vitreoretinal diseases. A graduate of the Massachusetts Institute of Technology and the University of Illinois College of Medicine, he completed his residency at the Massachusetts Eye and Ear Infirmary and a fellowship in vitreoretinal diseases at the Bascom Palmer Eye Institute. Dr. D’Amico is a distinguished national and international lecturer and is the recipient of many honors, including the Life Achievement Award from the American Academy of Ophthalmology. He is highly active in professional societies, including past president of the Retina Society, and he is the immediate past president of the prestigious international retinal society Club Jules Gonin.

Frank Holz, FEBO, FARVO

University of Bonn

Prof Holz is professor and chair of the Department of Ophthalmology at the University of Bonn, Germany. His scientific interests include the pathogenesis, prognostic factors, biomarkers and treatment of macular and retinal diseases, and innovative retinal imaging technologies. He trained at the University of Heidelberg, Germany, and completed a fellowship at Moorfields Eye Hospital, London, with Professor Alan C. Bird.

Professor Holz is a co-founder of the Priority Program AMD of the German Research Council (DFG) and the GRADE Reading Centre in Bonn. He is a board member of the German Ophthalmological Society (DOG) and EURETINA, member of the European Academy of Ophthalmology, the Macula Society, the Club Jules Gonin, editor-in-chief of Der Ophthalmologe, and serves as a reviewer for many peer-reviewed journals. He has received numerous awards, including the Leonhard-Klein Award for Ocular Surgery, the Alcon Research Institute (ARI) award and the Senior Achievement Award of the American Academy of Ophthalmology. He has published more than 250 articles in peer-reviewed journals and is the editor of several books on retinal disease.

Giovanni Staurenghi, MD, FARVO, FEBO

Luigi Sacco Hospital

Dr. Giovanni Staurenghi is presently Professor of Ophthalmology and Chairman of the University Eye Clinic and director of the University Eye Clinic Department of Biomedical and Clinical Science “Luigi Sacco” at the Luigi Sacco Hospital in Milan, Italy. He received his medical degree at the University of Pavia and his residency training at the University of Milan, both in Italy. He was a research fellow and, subsequently, a visiting scientist at the Schepens Eye Research Institute.

Dr. Staurenghi is a member of the Macula Society, Association for Research in Vision and Ophthalmology (ARVO), Ophthalmic Photographer Society, and American Academy of Ophthalmology; a member of the editorial board of IOVS; and a reviewer for many international scientific journals. He was a member of the Annual Meeting Program Committee of ARVO from 2008 to 2010, is a scientific advisor for the Digital Angiography Reading Center, and a visiting professor and consultant for the Belfast Ophthalmic Reading Center at the Central Angiographic Resource Facility.

Jordi Monés, MD, PHD

Institut de la Màcula

Dr. Jordi Monés is the Director of the Institut de la Màcula and the Director, Principal Investigator, and one of the founder governors of the Barcelona Macula Foundation: Research for Vision.

Dr. Monés earned his degree and his PhD cum laude in medicine and surgery at the Universitat de Barcelona, Spain. He specialized in ophthalmology at the Centro de Oftalmología Barraquer, Universitat Autònoma de Barcelona from 1986-1989. He completed his Research Retina Fellowship at the Massachusetts Eye and Ear Infirmary (MEEI) at Harvard University, Boston, USA in 1990 and 1991 and a Clinical Retina Fellowship at the Hospital San José at the Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM), Mexico in 1992.

Dr. Monés was also board member of Futbol Club Barcelona and the Commissioner of the Barça Innovation Hub and of the Sports Science Department (Medical, Performance, and Technology) from 2010 to 2017. In his commitment for improving public health, he envisioned and achieved the FCB stadium smoke-free policy, the only one in Spain even today. This accomplishment resulted in several prizes and public recognition, including from the European Commission.

His research fields of interest are the pathophysiology, imaging, and emerging therapies for AMD and retinal degenerative diseases, with particular interest in the end-stage atrophic form, regenerative approaches with stem cells and gene therapy, microbiome, and clinical biophotonics.

Ramin Tadayoni, MD, PHD

Lariboisere University Hospital

Dr. Ramin Tadayoni is Professor of Ophthalmology at University of Paris and Head of the Department of Ophthalmology at Lariboisière University Hospital (Paris, France). He has authored more than 140 medical and scientific articles and has made numerous contributions to ophthalmology textbooks. Dr. Tadayoni completed undergraduate training in medicine at the University of Marseille, and his MD and internship at Paris V University. He completed his studies with a retina fellowship at Lariboisière University Hospital. Simultaneously, he pursued his PhD in science at Paris VII University and the Paris Vision Institute.

Tien Wong, FRCS, PHD, FARVO

Singapore National Eye Centre

Dr. Tien Wong is currently the Professor and Chair of the Ophthalmology and Visual Science Program and Medical Director of the Singapore National Eye Center. He is concurrently Vice-Dean, Office of Clinical Sciences at the Duke-NUS Medical School, National University of Singapore. He was previously Executive Director of the Singapore Eye Research Institute, Chairman of the Department of Ophthalmology at the National University of Singapore and Chairman of the Department of Ophthalmology at the University of Melbourne, Australia.

Dr. Wong balances clinical practice in ophthalmology, focusing on retinal diseases such as diabetic retinopathy and age-related macular degeneration, with a broad-based research program comprising epidemiological, clinical, and translational studies of Asian eye diseases, and on the use of retinal imaging to predict disease risk. He has authored >1,000 peer-reviewed papers, including papers in the New England Journal of Medicine, the Lancet, JAMA, and Nature; given >300 invited plenary, symposium, and named lectures; and received >US$50 million in grant funding. He has received numerous awards, including the Alcon Institute Research Award, the Arnall Patz Award from the Macula Society, and Singapore's President’s Science Award.

Yuichiro Ogura, MD

Nagoya City University Graduate School of Medical Sciences

Dr. Yuichiro Ogura is Professor and Chairman, Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medicine, Nagoya, Japan. Dr. Ogura's research interests focus on microcirculation of the retina and choroid, ocular drug delivery systems, and the pathophysiology of vitreoretinal diseases such as diabetic retinopathy and age-related macular degeneration. He has been an active member of ISER, ARVO, and AAO for many years. He is an Executive Board Member of The Japan Ophthalmological Society and other related societies in Japan. Dr. Ogura has presented many papers at various international congresses and organized several symposia at the recent ICER meetings.

Arshad Khanani, MD, MA

Managing Partner, Director of Clinical Research, Director of Fellowship, Sierra Eye Associates
Clinical Associate Professor, University of Nevada, Reno School of Medicine Reno, Nevada

Arshad M. Khanani, MD, MA, is Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine. He is a fellowship-trained vitreoretinal specialist and is certified by the American Board of Ophthalmology. As an undergraduate, Dr. Khanani was honored twice with the Howard Hughes Medical Institute Research Award. During his medical training, he received several research awards and designed multiple prospective clinical trials, which led to publications in major ophthalmology journals.

Due to his strong interest in clinical research, Dr. Khanani founded the clinical research section at Sierra Eye Associates. He has been a principal investigator for more than 50 clinical trials and has been a top enroller in the world for multiple Phase 1-3 trials. Dr. Khanani also serves as a member of clinical trial steering committees and scientific advisory boards for multiple companies. His articles have been published in top ophthalmology journals. Dr. Khanani has also presented his work at major ophthalmology meetings worldwide and has been invited multiple times as a guest speaker nationally and internationally.

Dr. Khanani has received numerous awards of distinction. He is an elected member of the Retina Society. He has received the Albert Nelson Marquis Lifetime Achievement Award. He has also received the Honor Award and the Senior Honor Award from the American Society of Retina Specialists for his contributions. Dr. Khanani has also been consistently named one of America’s Top Ophthalmologists and has also been included in The Leading Physicians of the World publication. In 2019, he received the Nevada Business Magazine Healthcare Heroes Physician of the Year award for his continued dedication to the field of ophthalmology.

Carl Danzig, MD

Rand Eye Institute

Dr. Carl Danzig joined Rand Eye Institute as Director of Vitreoretinal Services in July 2011.

He is experienced in the treatment of macular degeneration, macular edema, diabetic retinopathy, retinal detachment, retinal vein occlusion, and other disorders. In order to help patients with these conditions restore or preserve their eyesight, he offers a range of surgical procedures, including intravitreal injections, retina laser treatments, pneumatic retinopexy, scleral buckle, pars plana vitrectomy, and pars plana lensectomy.

He received his medical degree from the Temple University School of Medicine in Philadelphia, completed his internship at Crozer-Chester Medical Center in Upland, Pennsylvania, and ophthalmology residencies at Martin Luther King Jr. Hospital/Charles R. Drew University in Los Angeles and State University of New York-Downstate in Brooklyn, New York.

Subsequent to his residency training, Dr. Danzig underwent a two-year vitreoretinal fellowship at the University of Texas/Southwestern Medical Center in Dallas.

Board certified by the American Board of Ophthalmologists, Dr. Danzig is licensed to practice medicine in Texas and Florida. He has lectured internationally and presented at meetings of major ophthalmologic organization. In addition, he has authored numerous articles that have been published in prestigious medical journals.

Charles C. Wykoff, MD, PhD

Retina Consultants of Houston

Dr. Charles C. Wykoff is Director of Research at Retina Consultants of Houston and elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. He graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his medical degree from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. He completed ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute where he served as Chief Resident/Co-Director of Ocular Trauma and was awarded a Heed Fellowship and the Ronald G. Michels Fellowship Award. Dr. Wykoff is passionate about translational research and clinical trial design, and has published over 130 peer-reviewed manuscripts.

His research interests pertain to angiogenesis and retinal vascular diseases, including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgical topics such as retinal detachment and macular surgery. Dr. Wykoff has been awarded the AAO Secretariat and Achievement Awards as well as the ASRS Honor and Senior Honor Awards. He was a founding member of the Ophthalmology Retina Editorial Board and is involved with multiple scholarly societies including the Macula Society, the Retina Society, and the Vit-Buckle Society. He is actively involved in entrepreneurial activities and serves on multiple scientific advisory boards for companies spanning the innovative process from early to late stage development. His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for blinding diseases.

David Eichenbaum, MD

Retina Vitreous Associates of Florida

Dr. David Eichenbaum is a board-certified ophthalmologist fellowship-trained in diseases and surgery of the vitreous and retina. He has been practicing in Tampa Bay since 2007. He completed his medical degree and ophthalmology residency at the University of South Florida in Tampa, where he served as Chief Resident. Dr. Eichenbaum completed his two-year surgical retina fellowship at Tufts New England Eye Center and Ophthalmic Consultants of Boston.

Dr. Eichenbaum has published in numerous professional journals, textbook chapters, and has presented his work at the American Society of Retinal Specialists, American Academy of Ophthalmology, and the Association of Research and Vision in Ophthalmology meeting. He speaks nationally on molecular eye medications for diseases such as macular degeneration, retinal vascular occlusions, and diabetes, and has served on numerous clinical advisory boards. Dr. Eichenbaum is principal investigator for multiple clinical trials in the practice dealing with diabetic and macular degenerative disease.

Dr. Eichenbaum is a Fellow of the American Academy of Ophthalmology, sits on the board of the Florida Society of Ophthalmology, and has served as past president of the Tampa Bay Ophthalmic Society. In 2015, he received the Michael R. Redmond, MD Outstanding Young Ophthalmologist Award from the Florida Society of Ophthalmology. He is a member of the American Society of Retina Specialists, the Vit-Buckle Society, Club Vit, the Florida Society of Ophthalmology, and the Tampa Bay Society of Ophthalmology.

David R Lally, MDD

New England Retina Consultants

Dr. David R. Lally graduated from Vanderbilt University and received a medical degree from Jefferson Medical College in Philadelphia, PA. He completed his ophthalmology residency at the Wills Eye Hospital in Philadelphia, and then went on to a fellowship in Vitreoretinal Diseases and Surgery at Tufts/New England Eye Center and Ophthalmic Consultants of Boston. Dr. Lally is board certified and is an active member of the American Society of Retinal Specialists (ASRS), the American Academy of Ophthalmology (AAO), and the Association for Research in Vision and Ophthalmology (ARVO). He is an attending surgeon at Baystate Medical Center and an Assistant Professor of the Department of Surgery at the University of Massachusetts Medical School-Baystate. In addition, he is an Assistant Professor of the Department of Ophthalmology at Tufts University School of Medicine. Dr. Lally has published numerous research manuscripts and book chapters including over 20 peer-reviewed articles. He has publications in the distinguished New England Journal of Medicine (NEJM) and JAMA Ophthalmology, and he presents lectures at local and national meetings every year. He has participated as a research investigator in over 20 clinical trials for age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, diabetic macular edema, macular telangiectasia, retinal detachment, and vitreomacular adhesion. He acts as the principal investigator for all clinical trials at the Retina Research Institute at New England Retina Consultants. He also serves as a manuscript reviewer for several academic journals including JAMA Ophthalmology, OSLI Retina, Retinal Cases & Brief Reports, Journal of Cataract and Refractive Surgery, and the Cleveland Clinic Journal of Medicine.

Jared S. Nielsen, MD, MBA

Wolfe Eye Clinic

Dr. Jared S. Nielsen is a board-certified and fellowship-trained retina specialist. He earned his medical degree along with a master’s degree in pathology in a combined degree program at the Chicago Medical School in Chicago, Illinois. Following a transitional internship at the University of Hawaii in Honolulu, Hawaii, he completed an ophthalmology residency at Loyola University Chicago in Chicago, Illinois.

Dr. Nielsen completed a vitreoretinal surgery fellowship at Northwestern University in Chicago, Illinois, where he remains a Clinical Instructor of Ophthalmology. He joined Wolfe Eye Clinic in 2007. He is a frequent lecturer and is the Program Director for Wolfe Eye Clinic’s Retina Fellowship. Dr. Nielsen completed an additional master’s degree in business administration from the University of Iowa Tippie College of Business in 2018.

Dr. Nielsen is known as an active eye care researcher and he participates in clinical trials designed to provide better care to patients who suffer from sight-threatening retinal diseases. He has served as a principal investigator in over 40 clinical trials advancing care for patients who suffer from blinding diseases including: wet and dry macular degeneration, diabetic retinopathy, and central serous chorioretinopathy. He is engaged as an investigator in the DRCR Retina Network, a National Eye Institute sponsored effort to study retinal disease. Dr. Nielsen is also an author and reviewer for peer-reviewed retina journals and presents at major retina meetings throughout the world.

Jason Hsu, MD

Wills Eye Hospital

Dr. Jason Hsu is an attending surgeon on the Retina Service of Wills Eye Hospital. He graduated cum laude from Princeton University with a BSE in electrical engineering and a certificate in engineering biology. While at Princeton, he received the Manfred Pyka Memorial Physics Prize in 1993, the Newport-Klinger Research Award in 1996, and was elected to the Sigma Xi Research Honor Society. He went on to graduate from the University of Pennsylvania School of Medicine, where he was elected to the Alpha Omega Alpha Medical Honor Society. He completed his internship at Scripps Mercy Hospital in San Diego, CA.

Dr. Hsu performed his ophthalmology residency at the University of Pennsylvania, Scheie Eye Institute and was awarded a National Eye Institute Travel Fellowship in 2003. He completed his vitreoretinal surgery fellowship at Wills Eye Hospital.

Dr. Hsu is board certified in ophthalmology and is a member of the American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, American Medical Association, Pennsylvania Medical Society, and the Greater Philadelphia Ophthalmic Society. He is a member of the Retina Service at Wills Eye Hospital and an Associate Professor of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Hsu serves as a lecturer for the Medical Resident Education Program at Wills Eye Hospital.

Jeffrey Heier, MD

Ophthalmic Consultants of Boston

Dr. Jeffrey Heier is the Co-President and Medical Director of Ophthalmic Consultants of Boston (OCB). He is a leading researcher for new treatments in vitreoretinal disease, surgical techniques, and diagnostic imaging of the retina. Dr. Heier is on the Executive Board of the Retina Society and the ASRS and is Immediate past president of the New England Ophthalmological Society. He is a scientific advisor to many biotechnical or pharmaceutical companies, lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center, and vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.

Peter Kaiser, MD

Cole Eye Institute

Dr. Peter K. Kaiser graduated magna cum laude with Highest Honors from Harvard College and Harvard Medical School. He completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute, Cleveland, Ohio. As a National Institute of Health-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration (AMD) and diabetic retinopathy. In addition, Dr. Kaiser is actively involved in clinical research as Study Chairman of five major, multi-center, international clinical trials, and principal investigator in numerous studies for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR). Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored seven textbooks, and more than 250 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Senior Achievement Awards and is listed as one of the “Best Doctors in America.” Finally, he is the team ophthalmologist for the Cleveland Cavaliers (National Basketball Association).

Sunil S. Patel, MD, PhD

West Texas Retina Consultants

Dr. Sunil Patel is a distinguished ophthalmologist practicing in Abilene, Texas. He is the founder of West Texas Retina Consultants.

Dr. Patel obtained his bachelor of science in biochemistry at UCLA. He continued furthering his education at the University of Texas Southwestern Graduate School of Biomedical where he obtained his doctor of philosophy sciences in immunology and also his doctor of medicine at the University of Texas Southwestern Medical School.

As a medical doctor he performed his internship at Presbyterian Hospital in Dallas and his residency specializing in ophthalmology at the Doheny Eye Institute in Los Angeles, California. It is at the Doheny Eye Institute that he completed his fellowship for Surgical and Medical Vitreoretinal and Uveitis.

Dr. Patel has been engaged in clinical research for 20 years, and is the Founder of Integrated Clinical Research dba Retina Research Institute of Texas located in his West Texas office in Abilene. He along with his colleagues strive to stay abreast of the newest innovative treatments and research for the well-being of their patients' vision.

Veeral Sheth, MD, MBA, FACS

University Retina

Dr. Veeral Sheth is a native Chicagoan who specializes in diseases of the retina and vitreous. He is a Clinical Assistant Professor at the University of Illinois at Chicago. Dr. Sheth completed his undergraduate and medical school training at the University of Illinois at Chicago. He went on to complete his ophthalmology residency at the Illinois Eye and Ear Infirmary where he served as Chief Resident. After residency, Dr. Sheth moved to the University of Chicago for fellowship in retinal surgery.

Dr. Sheth joined University Retina after directing retinal services at four hospitals in the Chicagoland area. In addition, he continues to teach physicians and students at the University of Illinois at Chicago.

Dr. Sheth is actively involved in clinical research including national trials for age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. His efforts in research have resulted in many peer-reviewed publications, meeting abstracts, and textbook chapters.

SriniVas R. Sadda, MD

UCLA Stein Eye Institute, Doheny Eye Institute

Dr. SriniVas R. Sadda is the President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine. He received his MD from Johns Hopkins University, where he also completed his ophthalmology residency and neuro-ophthalmology and medical retina fellowships (Wilmer Eye Institute).

Dr Sadda’s major research interests include automated retinal image analysis, retinal substructure assessment, and advanced retinal imaging technologies. He has more than 380 peer-reviewed publications and 13 book chapters, and has given over 350 presentations worldwide. Dr. Sadda also serves as an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Graefe’s, Ophthalmology Retina, and Ophthalmology. He is also an editor of the 5th edition of the Ryan’s Retina textbook. Among Dr. Sadda’s awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, an Achievement Award and a Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, the Macula Society Young Investigator Award, Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award, The Macula Society Paul Henkind Lecture and Award, and American Society of Retina Specialists Young Investigator Award. He has also received the Silver Fellow designation from the Association for Research in Vision and Ophthalmology. He has been named to the Best Doctors of America list for several consecutive years.

Frank Holz, FEBO, FARVO

University of Bonn

Prof Holz is professor and chair of the Department of Ophthalmology at the University of Bonn, Germany. His scientific interests include the pathogenesis, prognostic factors, biomarkers and treatment of macular and retinal diseases, and innovative retinal imaging technologies. He trained at the University of Heidelberg, Germany, and completed a fellowship at Moorfields Eye Hospital, London, with Professor Alan C. Bird.

Professor Holz is a co-founder of the Priority Program AMD of the German Research Council (DFG) and the GRADE Reading Centre in Bonn. He is a board member of the German Ophthalmological Society (DOG) and EURETINA, member of the European Academy of Ophthalmology, the Macula Society, the Club Jules Gonin, editor-in-chief of Der Ophthalmologe, and serves as a reviewer for many peer-reviewed journals. He has received numerous awards, including the Leonhard-Klein Award for Ocular Surgery, the Alcon Research Institute (ARI) award and the Senior Achievement Award of the American Academy of Ophthalmology. He has published more than 250 articles in peer-reviewed journals and is the editor of several books on retinal disease.

Allen C. Ho, MD, FACS

Wills Eye Hospital

Dr. Allen C. Ho is an internationally recognized retina specialist specializing in state-of-art patient care and is a leader in the development of new medical and surgical treatments for retinal diseases such as age-related macular degeneration, macular diseases, diabetic retinopathy, and surgical retinal diseases. He is a Phi Beta Kappa graduate of Cornell University College of Arts and Sciences, receiving highest distinction in all subjects. He graduated from Columbia University College of Physicians and Surgeons and was elected Co-Chief Resident during his ophthalmology residency at Wills Eye Hospital. He completed a Fellowship in Vitreoretinal Diseases at Manhattan Eye, Ear and Throat Hospital where he was awarded a Heed Ophthalmic Fellowship. Currently, he is Attending Surgeon at Wills Eye Hospital and Director of Retina Research at Wills Eye Hospital. He is former Co-Director of the Wills Retina Fellowship, widely recognized as the premier retina training program in the country.

Dr. Ho is Professor of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University, Board Certified in Ophthalmology and a Fellow of the American College of Surgeons. He is an active member and leader in several societies including the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, The American Society of Retina Specialists, The Macula Society, The Retina Society, The Society of Heed Fellows, The Vail Vitrectomy Society, The Pennsylvania Academy of Ophthalmology, and The Greater Philadelphia Ophthalmic Society (past president). He serves on the Executive Committee and is President of the Retina Society.

David Brown, MD

Retina Consultants of Houston

Dr. David Brown graduated from Baylor College of Medicine with highest honors and completed ophthalmology and retina training at the University of Iowa where he was a Thomas Heed Fellow, a Hermann Knapp Fellow, and was awarded the Ron Michels Fellowship award presented to the top retinal surgery fellow in the US. His research and clinical interests are focused on macular surgery, age-related macular degeneration, retinal vascular disease, and diabetic retinopathy. He is an elected member of the Macula Society and the Retina Society and directs one of the largest clinical trial centers for retinal disease in the US.

Giovanni Staurenghi, MD, FARVO, FEBO

Luigi Sacco Hospital

Dr. Giovanni Staurenghi is presently Professor of Ophthalmology and Chairman of the University Eye Clinic and director of the University Eye Clinic Department of Biomedical and Clinical Science “Luigi Sacco” at the Luigi Sacco Hospital in Milan, Italy. He received his medical degree at the University of Pavia and his residency training at the University of Milan, both in Italy. He was a research fellow and, subsequently, a visiting scientist at the Schepens Eye Research Institute.

Dr. Staurenghi is a member of the Macula Society, Association for Research in Vision and Ophthalmology (ARVO), Ophthalmic Photographer Society, and American Academy of Ophthalmology; a member of the editorial board of IOVS; and a reviewer for many international scientific journals. He was a member of the Annual Meeting Program Committee of ARVO from 2008 to 2010, is a scientific advisor for the Digital Angiography Reading Center, and a visiting professor and consultant for the Belfast Ophthalmic Reading Center at the Central Angiographic Resource Facility.

Glenn J. Jaffe, MD

Duke Health

Dr. Glenn Jaffe is the Robert Machemer Professor of Ophthalmology and a member of the vitreoretinal faculty at Duke University Eye Center. He is chief of the vitreoretinal service and founded and directs the Duke Reading Center. Dr. Jaffe received his medical degree and his ophthalmology residency training at the University of California, San Francisco. He completed a two-year combined clinical and research vitreoretinal fellowship at the Medical College of Wisconsin. He joined the faculty at Duke University in 1989.

He has published over 210 articles in peer-reviewed journals and has an active clinical and basic science research program. Dr. Jaffe treats patients with a variety of medical and surgical vitreoretinal and uveitis diseases. His clinical research interests include the use of optical coherence tomography in clinical retinal treatment trials, novel medical and surgical therapies of uveitis and other posterior segment disorders. He has been a pioneer in the development of sustained drug delivery systems to treat ocular disease. He has participated in numerous clinical trials of new therapies for uveitis and vitreoretinal diseases. He directs a basic research program to investigate the mechanisms responsible for macular degeneration.

Jeffrey Heier, MD

Ophthalmic Consultants of Boston

Dr. Jeffrey Heier is the Co-President and Medical Director of Ophthalmic Consultants of Boston (OCB). He is a leading researcher for new treatments in vitreoretinal disease, surgical techniques, and diagnostic imaging of the retina. Dr. Heier is on the Executive Board of the Retina Society and the ASRS and is Immediate past president of the New England Ophthalmological Society. He is a scientific advisor to many biotechnical or pharmaceutical companies, lectures nationally and internationally, and has authored numerous, peer-reviewed works. Dr. Heier received his medical degree from Boston University, did an internship and residency at Fitzsimons Army Medical Center, and vitreoretinal fellowship at OCB/Tufts School of Medicine. Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.

Peter Kaiser, MD

Cole Eye Institute

Dr. Peter K. Kaiser graduated magna cum laude with Highest Honors from Harvard College and Harvard Medical School. He completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute, Cleveland, Ohio. As a National Institute of Health-funded investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration (AMD) and diabetic retinopathy. In addition, Dr. Kaiser is actively involved in clinical research as Study Chairman of five major, multi-center, international clinical trials, and principal investigator in numerous studies for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR). Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored seven textbooks, and more than 250 peer-reviewed papers. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Senior Achievement Awards and is listed as one of the “Best Doctors in America.” Finally, he is the team ophthalmologist for the Cleveland Cavaliers (National Basketball Association).

What's Going On?

Keep up-to-date with the latest news about Iveric Bio and its clinical developments.

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
05/05
Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results
- GATHER2 On-Track to Complete Enrollment in 3Q of this Year - - Conference Call and Webcast Today, May 5, 2021 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--May 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the quarter ended March 31, 2021 and
Posted: May 05, 2021
Read More
05/04
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--May 4, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on May 3, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to four newly hired, non-executive employees.
Posted: May 04, 2021
Read More
04/28
Iveric Bio to Report First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
NEW YORK --(BUSINESS WIRE)--Apr. 28, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021 . Following the announcement, the Iveric Bio management team will host a live conference call and webcast
Posted: April 28, 2021
Read More
04/05
David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
NEW YORK --(BUSINESS WIRE)--Apr. 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer , MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on
Posted: April 05, 2021
Read More
04/01
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Apr. 1, 2021-- IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on April 1, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
Posted: April 01, 2021
Read More
03/16
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Mar. 16, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 15, 2021 , the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.
Posted: March 16, 2021
Read More
03/03
Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
- Patient Enrollment for GATHER2 Clinical Trial of Zimura® for the Treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration Ahead of Target and Progressing Well; Completion of Enrollment Expected in 3Q of this Year - - Conference Call and Webcast Today, March 3, 2021 , at 8:00
Posted: March 03, 2021
Read More
03/02
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Mar. 2, 2021-- IVERIC bio, Inc. (Nasdaq:ISEE) today reported that on March 1, 2021 , the Company granted non-statutory stock options to purchase an aggregate of 41,500 shares of the Company’s common stock to 2 newly hired, non-executive employees.
Posted: March 02, 2021
Read More
02/25
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
NEW YORK --(BUSINESS WIRE)--Feb. 25, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President, and Pravin U. Dugel, M.D., Chief Strategy and Business Officer, will participate in a fireside chat at the Cowen 41 st Annual Health Care
Posted: February 25, 2021
Read More
02/24
Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021
NEW YORK --(BUSINESS WIRE)--Feb. 24, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021 . Following the announcement, the Iveric Bio management team will host a live conference
Posted: February 24, 2021
Read More
01/05
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Jan. 5, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on January 4, 2021 , the Company granted non-statutory stock options to purchase an aggregate of 28,000 shares of the Company’s common stock to two newly hired, non-executive employees.
Posted: January 05, 2021
Read More
12/17
Iveric Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Dec. 17, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President, will present an overview of the Company at the 39 th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14,
Posted: December 17, 2020
Read More
12/04
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Dec. 4, 2020-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 3, 2020 , the Company granted a newly hired employee equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan. The inducement grants were approved by the Company’s
Posted: December 04, 2020
Read More
11/02
Iveric Bio Reports Third Quarter 2020 Operational Highlights and Financial Results
- Conference Call and Webcast Today, November 2, 2020 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Nov. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.
Posted: November 02, 2020
Read More
10/29
Iveric Bio to Participate in Upcoming Virtual Investor / Industry Conferences
NEW YORK --(BUSINESS WIRE)--Oct. 29, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following, upcoming, virtual investor conferences in November: 29 th Annual Credit Suisse Virtual Healthcare Conference Glenn P.
Posted: October 29, 2020
Read More
10/26
Iveric Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 2, 2020
NEW YORK --(BUSINESS WIRE)--Oct. 26, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020 . Following the announcement, the IVERIC bio management team will host a live conference call and
Posted: October 26, 2020
Read More
10/02
Iveric Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Oct. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on October 1, 2020 , the Company granted a newly hired employee a non-statutory option to purchase 14,000 shares of the Company’s common stock. This grant was made pursuant to the Company’s 2019
Posted: October 02, 2020
Read More
09/03
Iveric Bio to Participate in Upcoming September Investor / Industry Conferences
NEW YORK --(BUSINESS WIRE)--Sep. 3, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following upcoming virtual investor conferences in September: Citi 15 th Annual BioPharma Virtual Conference 2020 on Wednesday, September 9 and Thursday, September 10,
Posted: September 03, 2020
Read More
09/02
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Sep. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on September 1, 2020 , the Company granted non-statutory stock options to purchase an aggregate of 34,000 shares of the Company’s common stock to two newly hired, non-executive employees.
Posted: September 02, 2020
Read More
09/01
Iveric Bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology
NEW YORK --(BUSINESS WIRE)--Sep. 1, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to
Posted: September 01, 2020
Read More
08/05
Iveric Bio Reports Second Quarter 2020 Operational Highlights and Financial Results
- Conference   Call and Webcast Today, August 5, 2020 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Aug. 5, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.
Posted: August 05, 2020
Read More
08/04
Iveric Bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
NEW YORK --(BUSINESS WIRE)--Aug. 4, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, MD, Executive Vice President and Chief Strategy and Business Officer, will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August
Posted: August 04, 2020
Read More
08/03
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Aug. 3, 2020-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on August 3, 2020 , the Company granted Dhaval Desai , the Company’s newly hired Chief of Staff, equity based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan.
Posted: August 03, 2020
Read More
07/29
Iveric Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
NEW YORK --(BUSINESS WIRE)--Jul. 29, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020 . Following the announcement, the IVERIC bio management team will host a live conference call and
Posted: July 29, 2020
Read More
07/16
Iveric Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
–   A Biotechnology Industry Leader and Internationally Known Vitreo-Retinal Specialist with Notable Expertise in Pharmaceuticals for Age-Related Macular Degeneration and Ocular Gene Therapy – NEW YORK --(BUSINESS WIRE)--Jul. 16, 2020-- IVERIC bio, Inc.
Posted: July 16, 2020
Read More
06/30
Iveric Bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
NEW YORK --(BUSINESS WIRE)--Jun. 30, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of
Posted: June 30, 2020
Read More
06/22
Iveric Bio Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
NEW YORK --(BUSINESS WIRE)--Jun. 22, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the closing of its underwritten public offering of 28,503,220 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock,
Posted: June 22, 2020
Read More
06/18
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
NEW YORK --(BUSINESS WIRE)--Jun. 18, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 24,535,720 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common
Posted: June 18, 2020
Read More
06/17
Iveric Bio Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement
NEW YORK --(BUSINESS WIRE)--Jun. 17, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $50.0 million of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof).
Posted: June 17, 2020
Read More
06/15
Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial
- 28% Relative Benefit for Zimura 2 mg at 18 Months -   - Second Phase 3 Clinical Trial to Initiate this Month -   - Conference Call and Webcast Today, June 15, 2020 at 8:00am ET - NEW YORK , June 15, 2020 /PRNewswire/ --  IVERIC bio, Inc.  (Nasdaq: ISEE) today announced positive 18 month results
Posted: June 15, 2020
Read More
06/14
Iveric Bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020
NEW YORK --(BUSINESS WIRE)--Jun. 14, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report 18 month data from the Zimura ® (avacincaptad pegol) OPH2003 Phase 3 randomized, controlled clinical trial in geographic atrophy secondary to age-related macular degeneration on Monday,
Posted: June 14, 2020
Read More
06/02
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Jun. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on June 1, 2020 , the Company granted non-statutory stock options to purchase an aggregate of 34,000 shares of the Company’s common stock to two newly hired, non-executive employees.
Posted: June 02, 2020
Read More
05/27
Iveric Bio to Present at the Jefferies 2020 Healthcare Conference
NEW YORK --(BUSINESS WIRE)--May 27, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin Dugel , MD, Executive Vice President and Chief Strategy and Business Officer will present an overview of the Company at the Jefferies 2020 Virtual Healthcare Conference , on Wednesday, June 3 at
Posted: May 27, 2020
Read More
05/06
Iveric Bio Reports First Quarter 2020 Operational Highlights and Financial Results
- Conference Call and Webcast Today, May 6, 2020 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--May 6, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended March 31, 2020 and provided a general business update.
Posted: May 06, 2020
Read More
05/04
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--May 4, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on May 1, 2020 , the Company granted a newly hired, non-executive employee a non-statutory stock option to purchase 33,000 shares of the Company’s common stock.
Posted: May 04, 2020
Read More
04/28
Iveric Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
NEW YORK --(BUSINESS WIRE)--Apr. 28, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2020 financial and operating results on Wednesday, May 6, 2020 . Following the announcement, the IVERIC bio management team will host a live conference call and webcast
Posted: April 28, 2020
Read More
04/03
Iveric Bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NEW YORK --(BUSINESS WIRE)--Apr. 3, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy
Posted: April 03, 2020
Read More
04/02
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Apr. 2, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on April 1, 2020 , the Company granted newly hired employees equity-based awards. The grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan (as amended), were approved by the
Posted: April 02, 2020
Read More
03/23
Iveric Bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer
- A Retinal Expert Recognized Globally in both the Medical Community and Biotech/Pharma Ophthalmic Industry - NEW YORK --(BUSINESS WIRE)--Mar. 23, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and
Posted: March 23, 2020
Read More
03/18
Iveric Bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NEW YORK --(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that due to the threat of the coronavirus (COVID-19) global pandemic, the Company has decided to delay the initiation of enrollment of patients in the second pivotal clinical trial for Zimura ® (avacincaptad pegol), a
Posted: March 18, 2020
Read More
03/03
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on March 2, 2020 , the Company granted a newly hired, non-executive employee a non-statutory stock option to purchase 18,500 shares of the Company’s common stock. In addition, on March 2, 2020 , the Company granted
Posted: March 03, 2020
Read More
02/27
Iveric Bio Reports Fourth Quarter and Year End 2019 Operational Highlights and Financial Results
- Conference Call and Webcast Today, February 27, 2020 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Feb. 27, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fourth quarter and full year ended December 31, 2019 and provided a general business update.
Posted: February 27, 2020
Read More
02/26
Iveric Bio to Present at the Cowen and Company 40th Annual Health Care Conference
NEW YORK --(BUSINESS WIRE)--Feb. 26, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Kourous A. Rezaei , M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 40 th Annual Health Care Conference in Boston, MA , on Wednesday, March 4 at 9:20 a.m.
Posted: February 26, 2020
Read More
02/20
Iveric Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020
NEW YORK --(BUSINESS WIRE)--Feb. 20, 2020-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020 . Following the announcement, the IVERIC bio management team will host a live
Posted: February 20, 2020
Read More
01/13
Iveric Bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
 - On-Track for First Patient Enrollment in 1Q 2020– - Company to Host R&D Symposium for Investors/Analysts on Tuesday January 14, 2020 in San Francisco, CA from 6:30 to 8:00 am (Pacific Time) - NEW YORK --(BUSINESS WIRE)--Jan. 13, 2020-- IVERIC bio, Inc.
Posted: January 13, 2020
Read More
12/19
Iveric Bio to Host an R&D Investor Symposium on Tuesday, January 14, 2020 in San Francisco, CA
- Featuring Zimura® Pivotal Program in Geographic Atrophy, Including the Design of the Second Pivotal Trial in GA - - Live Webcast to Begin at 6:30 a.m. Pacific Time - NEW YORK --(BUSINESS WIRE)--Dec. 19, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced details for its R&D Investor Symposium
Posted: December 19, 2019
Read More
12/19
Iveric Bio to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Dec. 19, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at
Posted: December 19, 2019
Read More
12/06
Iveric Bio Announces Pricing of Public Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Dec. 6, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $4.000 per share and, to certain investors in lieu of common stock,
Posted: December 06, 2019
Read More
12/05
Iveric Bio Announces Proposed Offering of Common Stock
NEW YORK --(BUSINESS WIRE)--Dec. 5, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof).
Posted: December 05, 2019
Read More
11/26
Iveric Bio to Present at Evercore ISI 2nd Annual HealthCONx Conference
NEW YORK --(BUSINESS WIRE)--Nov. 26, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Evercore ISI 2 nd Annual HealthCONx Conference in Boston on Tuesday, December 3,
Posted: November 26, 2019
Read More
11/25
Iveric Bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapy
- Globally Recognized Innovator Played a Key Role in the Discovery and Vector Development of New AAV Serotypes - NEW YORK --(BUSINESS WIRE)--Nov. 25, 2019-- IVERIC bio, Inc. (NASDAQ: ISEE) announced today the appointment of Guangping Gao , PhD, as Chief Strategist, Gene Therapy. Dr.
Posted: November 25, 2019
Read More
11/14
Iveric Bio to Host a Zimura® R&D Symposium for Investors / Analysts on November 20, 2019
- Live Webcast to Begin at 8:00 a.m. Eastern Time - NEW YORK --(BUSINESS WIRE)--Nov. 14, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced details for its previously announced Zimura® R&D Symposium for Investors being held in New York, NY on Wednesday, November 20, 2019 , from 8:00 a.m.
Posted: November 14, 2019
Read More
11/12
Iveric Bio Reports Third Quarter 2019 Operational Highlights and Financial Results
- Conference Call and Webcast Today, November 12, 2019 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Nov. 12, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today provided further details of the recently announced clinical trial results for the Company’s Zimura ® (avacincaptad pegol) program in
Posted: November 12, 2019
Read More
11/12
Iveric Bio Initiating Second Pivotal Clinical Trial of Zimura® in GA with 1Q 2020 Targeted for First Patient Enrolled
- Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials - - Zimura R&D Symposium for Investors/Analysts to be Held on November 20, 2019 - - Conference Call and Webcast Today, November 12, 2019 , at 8:00 a.m. ET – NEW YORK --(BUSINESS WIRE)--Nov.
Posted: November 12, 2019
Read More
11/05
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--Nov. 5, 2019-- IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on November 1, 2019 , the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company’s common stock. In addition, on November 1, 2019 , the Company granted
Posted: November 05, 2019
Read More
11/04
Iveric Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019
- Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 - NEW YORK --(BUSINESS WIRE)--Nov. 4, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 12, 2019 .
Posted: November 04, 2019
Read More
10/29
Iveric Bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer
- Former Genzyme and Sanofi Scientist Brings Extensive Experience in Ocular Gene Therapy with Viral Vectors to IVERIC bio - NEW YORK --(BUSINESS WIRE)--Oct. 29, 2019-- IVERIC bio, Inc. (NASDAQ:ISEE) announced today the appointment of Abraham Scaria , PhD, to the position of Chief Scientific
Posted: October 29, 2019
Read More
10/28
Iveric Bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Overall Data Suggest a Dose Response Relationship Across Treatment Groups - - Conference Call and Webcast Today, October 28, 2019 at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Oct. 28, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced initial topline data confirming that Zimura®
Posted: October 28, 2019
Read More
09/30
CORRECTING and REPLACING Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
  NEW YORK --(BUSINESS WIRE)--Sep. 30, 2019-- In the first sentence of the release, the date and time should read: Monday, October 7, 2019 at 8:00 a.m. Eastern Time (instead of: Monday, October 7, 2019 at 8:30 a.m. Eastern Time ). The corrected release reads:   IVERIC BIO TO PRESENT AT THE CHARDAN
Posted: September 30, 2019
Read More
09/30
Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
  NEW YORK --(BUSINESS WIRE)--Sep. 30, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3 rd Annual Genetic Medicines Conference in New York
Posted: September 30, 2019
Read More
09/17
Iveric Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Sep. 17, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Kourous A. Rezaei , MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on Tuesday, September 24, 2019 at
Posted: September 17, 2019
Read More
09/04
Iveric Bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019
- Featuring Company’s Emerging R&D Pipeline of Gene Therapies for the Treatment of Orphan Inherited Retinal Diseases – - Live Webcast to Begin at 8:30 a.m. Eastern Time - NEW YORK --(BUSINESS WIRE)--Sep. 4, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will host its inaugural Gene
Posted: September 04, 2019
Read More
08/07
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference
NEW YORK --(BUSINESS WIRE)--Aug. 7, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio , Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 14, 2019
Posted: August 07, 2019
Read More
08/01
Iveric Bio Reports Second Quarter 2019 Financial and Operating Results
- Company Continues to Expand its Gene Therapy Portfolio with the Addition of miniUSH2A Program - - Company to Host First Gene Therapy R&D Investor Day on September 13, 2019 - - Conference Call and Webcast Today, August 1, 2019 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Aug.
Posted: August 01, 2019
Read More
07/25
Iveric Bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
NEW YORK --(BUSINESS WIRE)--Jul. 25, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2019 financial and operating results on Thursday, August 1, 2019 . Following the announcement, IVERIC bio’s management team will host a live conference call and webcast
Posted: July 25, 2019
Read More
07/23
Iveric Bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program
NEW YORK --(BUSINESS WIRE)--Jul. 23, 2019-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation
Posted: July 23, 2019
Read More
06/17
Iveric Bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
NEW YORK & SOMERSET, N.J. --(BUSINESS WIRE)--Jun. 17, 2019-- IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics , today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product
Posted: June 17, 2019
Read More
05/08
Iveric Bio Reports First Quarter 2019 Financial and Operating Results
- Conference Call and Webcast Today, May 8, 2019 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--May 8, 2019-- IVERIC bio (Nasdaq: ISEE) today announced financial and operating results for the first quarter ended March 31, 2019 and provided a business update.
Posted: May 08, 2019
Read More
05/01
Iveric Bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
NEW YORK --(BUSINESS WIRE)--May 1, 2019-- IVERIC bio (Nasdaq:ISEE) today announced that it will report its first quarter 2019 financial and operating results on Wednesday, May 8, 2019 . Following the announcement, IVERIC bio’s management team will host a live conference call and webcast at 8:00
Posted: May 01, 2019
Read More
04/16
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio
- Company’s Shares Will Trade Under New Ticker Symbol: ISEE – NEW YORK --(BUSINESS WIRE)--Apr. 16, 2019-- Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited
Posted: April 16, 2019
Read More
04/11
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
NEW YORK --(BUSINESS WIRE)--Apr. 11, 2019-- Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania ( Penn ), including the Perelman School of Medicine at the
Posted: April 11, 2019
Read More
03/14
Ophthotech to Present at the Alliance for Regenerative Medicine’s (ARM) 7th Annual Cell & Gene Therapy Investor Day
NEW YORK --(BUSINESS WIRE)--Mar. 14, 2019-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei , M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative Medicine’s (ARM) 7 th Annual Cell and Gene Therapy Investor Day in New
Posted: March 14, 2019
Read More
03/06
Ophthotech to Present at the Cowen and Company 39th Annual Health Care Conference
NEW YORK --(BUSINESS WIRE)--Mar. 6, 2019-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei , M.D., Chief Medical Officer of Ophthotech , will present an overview of the Company at the Cowen and Company 39 th Annual Health Care Conference in Boston, MA , on Wednesday,
Posted: March 06, 2019
Read More
02/26
Ophthotech Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
- Conference Call and Webcast Today, February 26, 2019 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Feb. 26, 2019-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Posted: February 26, 2019
Read More
02/19
Ophthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019
NEW YORK --(BUSINESS WIRE)--Feb. 19, 2019-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019 . Following the announcement, Ophthotech’s management team will host a live
Posted: February 19, 2019
Read More
01/03
Ophthotech Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)--Jan. 3, 2019-- Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio , Chief Executive Officer and President, will present an overview of the Company at the 37th Annual J.P.
Posted: January 03, 2019
Read More
01/02
Ophthotech Announces the Addition of Ophthalmic Industry Leader, Calvin (Cal) W. Roberts, M.D., to Its Board of Directors
Dr. Roberts is Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University NEW YORK --(BUSINESS WIRE)--Jan. 2, 2019-- Ophthotech Corporation (NASDAQ: OPHT) announced today the election of
Posted: January 02, 2019
Read More
12/12
Ophthotech Announces the Addition of Ophthalmic Industry Leader, Adrienne L. Graves, Ph.D., Former Chief Executive Officer of Santen Inc., to Its Board of Directors
NEW YORK --(BUSINESS WIRE)--Dec. 12, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced today the election of Adrienne L. Graves , Ph.D., former Chief Executive Officer of Santen Inc. , the U.S. arm of Japan’s largest ophthalmic pharmaceutical company, to its Board of Directors, effective
Posted: December 12, 2018
Read More
11/12
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
NEW YORK --(BUSINESS WIRE)--Nov. 12, 2018-- Ophthotech Corporation (NASDAQ:OPHT) today announced the results from its Phase 2a safety trial of Zimura ® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD).
Posted: November 12, 2018
Read More
10/31
Ophthotech Reports Third Quarter 2018 Financial and Operating Results
- Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today - (Conference Call: Today, October 31, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the
Posted: October 31, 2018
Read More
10/31
Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)
- Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease - NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced
Posted: October 31, 2018
Read More
10/31
Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4
- Ophthotech Gains HtrA1 Inhibitors to Treat Age-related Retinal Diseases - - Versant Ventures Receives Equity Position in OPHT - - Conference Call and Webcast Today , October 31, 2018 at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)--Oct. 31, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced
Posted: October 31, 2018
Read More
10/23
Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018
NEW YORK --(BUSINESS WIRE)--Oct. 23, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and
Posted: October 23, 2018
Read More
10/04
Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Initial Top-line Zimura Geographic Atrophy Data Expected in the Fourth Quarter of 2019 - - Zimura Wet AMD Data Continues on Track for Initial Top-line Data Before the End of 2018 - NEW YORK --(BUSINESS WIRE)--Oct. 4, 2018-- Ophthotech Corporation (NASDAQ:OPHT) announced completion of patient
Posted: October 04, 2018
Read More
10/03
Ophthotech Corporation to Present at Chardan’s 2nd Annual Genetic Medicines Conference
NEW YORK --(BUSINESS WIRE)--Oct. 3, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Keith Westby , Chief Operating Officer, will present an overview of the Company at Chardan’s 2 nd Annual Genetic Medicines Conference , on Tuesday, October 9, 2018 at 8:30 a.m. Eastern Time .
Posted: October 03, 2018
Read More
08/22
Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
- Preclinical Proof-of-Concept Results in a Large Animal Model Published Online Ahead of Print in PNAS - NEW YORK --(BUSINESS WIRE)--Aug. 22, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that scientists at the University of Pennsylvania ( Penn ) and University of Florida published
Posted: August 22, 2018
Read More
08/01
Ophthotech Reports Second Quarter 2018 Financial and Operating Results
(Conference Call and Webcast Today, August 1, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--Aug. 1, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2018 and provided a business update.
Posted: August 01, 2018
Read More
07/25
Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018
NEW YORK --(BUSINESS WIRE)--Jul. 25, 2018-- Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2018 financial and operating results on Wednesday, August 1, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and
Posted: July 25, 2018
Read More
06/07
Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
- Expands Gene Therapy Portfolio with a Novel Mutation Independent Product Candidate for Autosomal Dominant Retinitis Pigmentosa - - Phase 1/2 Clinical Trial Expected to Initiate in Early 2020 - NEW YORK --(BUSINESS WIRE)--Jun. 7, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that it
Posted: June 07, 2018
Read More
05/09
Ophthotech Reports First Quarter 2018 Financial and Operating Results
(Conference Call and Webcast Today, May 9, 2018 , at 8:00 a.m. ET ) NEW YORK --(BUSINESS WIRE)--May 9, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update.
Posted: May 09, 2018
Read More
05/01
Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura® in Combination with Anti-VEGF Therapy in Wet Age-Related Macular Degeneration
- Initial Top-line Data Expected by the End of 2018 - NEW YORK --(BUSINESS WIRE)--May 1, 2018-- Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura ® (avacincaptad pegol), the Company’s complement factor C5 inhibitor,
Posted: May 01, 2018
Read More
05/01
Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
NEW YORK --(BUSINESS WIRE)--May 1, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018 . Following the announcement, Ophthotech’s management team will host a live conference call and webcast
Posted: May 01, 2018
Read More
03/06
Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference
NEW YORK --(BUSINESS WIRE)--Mar. 6, 2018-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20
Posted: March 06, 2018
Read More
02/27
Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
(Conference Call and Webcast Today, February 27, 2018 , at 8:00 a.m. ET ) - Ophthotech Targets Novel Gene Therapy Technology for Orphan and Age-Related Retinal Diseases - - Complement C5 Inhibitor, Zimura ® , on Track with Four Ongoing Ophthalmic Clinical Programs - NEW YORK --(BUSINESS WIRE)--Feb.
Posted: February 27, 2018
Read More
02/27
Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy
– Ophthotech collaborates with University of Massachusetts Medical School on novel technology for next-generation gene delivery technology and novel gene therapies for ophthalmic diseases – – Collaboration is led by Guangping Gao and Hemant Khanna at UMass Medical School’s Horae Gene Therapy Center
Posted: February 27, 2018
Read More
02/21
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018
NEW YORK --(BUSINESS WIRE)--Feb. 21, 2018-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018 . Following the announcement, Ophthotech’s management team will host a live
Posted: February 21, 2018
Read More
01/16
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
- One of the Largest Interventional Clinical Trials for the Treatment of STGD1, an Inherited Orphan Retinal Disease – - Zimura Is Also Being Investigated in Ongoing Clinical Trials for the Treatment of Dry and Wet Age-related Macular Degeneration (AMD) and Idiopathic Polypoidal Choroidal
Posted: January 16, 2018
Read More
01/16
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors
NEW YORK --(BUSINESS WIRE)--Jan. 16, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Jane Pritchett Henderson , Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics , to its Board of Directors, effective immediately. Ms.
Posted: January 16, 2018
Read More
01/02
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)--Jan. 2, 2018-- Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Posted: January 02, 2018
Read More
11/08
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
(Conference Call and Webcast Today, November 8, 2017 , at 8:00 a.m. ET ) - Complement C5 Inhibitor, Zimura ® , on Track to Have Four Ophthalmic Clinical Programs Ongoing by Year End - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results
Posted: November 08, 2017
Read More

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More